---
title: Phase 2 Study of CVN424
euct_id: 2024-516811-25-00
phase: Phase 4
status: Recruiting
sponsor: Cerevance Beta Inc.
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-516811-25-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-516811-25-00"
ctis_last_updated: "2026-04-15T03:38:02.026260908"
source: EU Clinical Trials Information System (CTIS)
---
# Phase 2 Study of CVN424

**EU CT Number:** [2024-516811-25-00](https://euclinicaltrials.eu/ctis-public/view/2024-516811-25-00)

## Key Facts

- **Phase:** Phase 4
- **Status:** Recruiting
- **Sponsor:** Cerevance Beta Inc.
- **Start Date:** 2025-03-31
- **Completion Date:** 2026-07-31
- **Conditions:** Parkinson Disease, Parkinson's disease
- **Interventions:** CVN424, film-coated tablets for oral administration

## Member States

Trial is authorized in 5 member states: Czechia, France, Italy, Poland, Spain.

## Sites (30)

- Neurologia  Śląska Centrum Medyczne, Katowice, Poland
- Neuro-Care Sp. z o.o. sp.k., Katowice, Poland
- Etg Neuroscience Sp. z o.o., Warsaw, Poland
- Centrum Zdrowia I Urody Maxxmed, Lublin, Poland
- Niepubliczny Zaklad Opieki Zdrowotnej Wielospecjalistyczna Poradnia Lekarska Synapsis Lech Szczechowski, Katowice, Poland
- Azienda Ospedaliera di Padova, Padova, Italy
- Irccs San Raffaele Roma S.r.l., Cassino, Italy
- Ospedale San Raffaele S.r.l., Milan, Italy
- Irccs San Raffaele Roma S.r.l., Rome, Italy
- Fondazione Istituto Neurologico Nazionale Casimiro Mondino, Pavia, Italy
- Assistance Publique Hopitaux De Paris, Creteil Cedex, France
- Hospices Civils De Lyon, Bron, France
- Centre Hospitalier Universitaire De Montpellier, Montpellier Cedex 5, France
- Centre Hospitalier Universitaire De Nice, Nice, France
- Centre Hospitalier Universitaire De Lille, Lille Cedex, France
- Centre Hospitalier Universitaire De Toulouse, Toulouse, France
- Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
- Policlinica Gipuzkoa S.A., Donostia, Spain
- Hospital Universitario De La Princesa, Madrid, Spain
- Hospital Universitario De Cruces, Barakaldo, Spain
- University Hospital Virgen Del Rocio S.L., Sevilla, Spain
- Hospital Universitari General De Catalunya, Sant Cugat Del Valles, Spain
- Hospital Clinic De Barcelona, Barcelona, Spain
- Hospital Universitario Y Politecnico La Fe, Valencia, Spain
- Praglandia s.r.o., Prague, Czechia
- Nemocnice Pardubickeho kraje a.s., Pardubice, Czechia
- Fakultni Nemocnice U Sv Anny V Brne, Brno-Stred, Czechia
- Vseobecna Fakultni Nemocnice V Praze, Prague, Czechia
- Axon Clinical s.r.o., Prague 5, Czechia
- Neurologie – doc. MUDr. Radomír Taláb, CSc., Hradec Králové, Czechia

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson Disease; Parkinson's disease
Age groups: elderly 65+, adults 18-64
Sex: male, female
Includes a vulnerable population.

Period: Screening
Screening

Period: Treatment
Participants will be randomized to receive once-daily oral doses of either 75 mg CVN424, 150 mg CVN424, or a matching placebo for 12 weeks.
Arms:
  - Low Dose: CVN424 75 mg per day
  - High Dose: CVN424 150 mg per day
  - Placebo: Placebo

Period: Follow-up
After the treatment end (Week 12) the patients will be 2 weeks under a safety follow-up. It ends with a safety visit on Week 14.
Arms:
  - Low Dose: CVN424 75 mg per day
  - High Dose: CVN424 150 mg per day
  - Placebo: Placebo
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-516811-25-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-516811-25-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-516811-25-00*